Month: June 2022

WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinforce the robust efficacy and safety profile of EMPAVELI®/Aspaveli® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with EMPAVELI resulted in meaningful improvements in quality of life for treatment-naïve patients and suggested the incidence of thrombosis was comparable to eculizumab, a C5 inhibitor. Additionally, a matching-adjusted indirect comparison (MAIC) showed significant improvements in clinical outcomes in treatment-naïve patients who received EMPAVELI compared to C5 inhibitors. “The...

– As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed:52% had reductions in mutant allele frequencies, including ASXL1 85% of evaluable patients demonstrated improved or stable fibrosis scores 90% of transfusion independent patients had stable or improved hemoglobin– MF patients initially treated in this Phase 2 study have rolled into an extension study to evaluate longer term safety and impact of bomedemstat on natural history of MF – – Evaluation of bomedemstat in combination with ruxolitinib in patients with MF who have a sub-optimal response to JAK inhibition or are JAK naive to commence – – Company to host virtual investor event on Saturday, 11 June 2022 at...

– The study completed enrollment with 73 patients in April 2022 – – As of the data cutoff of 29 April 2022, bomedemstat demonstrated durability of response with 81% of patients achieving normalized platelet counts for at least 12 weeks – – 58% of patients treated with bomedemstat experienced symptomatic improvement, defined as a decrease in Total Symptom Score, at 24 weeks – – Both JAK2 and CALR mutation burdens were decreased during treatment with bomedemstat – – The EHA data cut represents the last presentation before an End of Phase 2 meeting with FDA expected in 2H22 – – Company to host virtual investor event on Saturday,11 June 2022 at 10:30 AM ET- SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago” or the “company”)...

Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in patients 12 years of age and older. In addition, Phase 1 data of GBT021601 (GBT601), the company’s next-generation sickle hemoglobin (HbS) polymerization inhibitor, support its progression into the Phase 2 portion of a Phase 2/3 trial that is anticipated to commence by...

Swimmerplot Patient response rates following treatment with CB-010, single dose at dose level 1, in the ANTLER Phase 1 trialPatients With TEAEs Treatment emergent adverse events in the ANTLER Phase 1 trial— 100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as best response following 1 dose at the initial dose level in patients with aggressive r/r B-NHL — — First patient treated in the ANTLER trial remained in CR at 12 months — — Based on promising initial safety profile and clinical activity, ANTLER Phase 1 trial enrolling patients at dose level 2 — — CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve the persistence of antitumor activity — — Caribou webcast conference...

Press release Malmö, Sweden, June 10, 2022   Acarix signs additional commercial agreement in US and receives order for CADScor®System in Louisiana. Acarix continues the US expansion with another commercial partnership now covering Louisiana and parts of Mississippi. This partnership with Bio-Rhythms Inc provides access to cardiology clinics, emergency departments and primary care clinics in geographic areas with high medical need for rapid and cost-effective rule-out of coronary artery disease. Louisiana is among the top 5 US states based on death due to heart disease. The volume of patients and the need for rapid assessment and rapid rule out is high. Acarix’s CADScor®System has a strong potential to be a valuable aid in the rapid assessment of these patients and rule out those at low risk, creating more efficiency and focus on patients...

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute myeloid leukemia SAN MATEO, Calif. and CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, will present preclinical data today from studies of the company’s two novel investigational spleen tyrosine kinase (SYK) inhibitors, entospletinib and lanraplenib. The poster presentations will take place at the European Hematology Association (EHA) 2022 Congress in Vienna. The company is enrolling patients in clinical trials studying each compound and the preclinical data provide additional support for the biological rationale for the targeting of SYK in patients...

– AUTO4 shows high level of clinical activity with a novel targeting approach for patients with T Cell Lymphoma– AUTO1/22 demonstrates encouraging and durable responses in children ineligible for commercial CAR T product– Obe-cel shows high level of sustained clinical activity in B-NHL patients and first activity in Primary CNS Lymphoma Conference call to be held on Monday June 13, 2022 at 7:30 am EST/12:30 pm BST LONDON, June 10, 2022 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the publication of clinical data across multiple programs at the European Hematology Association (EHA) Congress, being held June 9-12, 2022. Autolus will hold a conference call on Monday June 13 2022 at 7:30...

UAB “Vilniaus prekyba” being the sole shareholder of AKROPOLIS GROUP, UAB (hereinafter – the Company) adopted resolution appointing PricewaterhouseCoopers, UAB (legal entity code 111473315) as the audit firm of the Company to perform the audit of the annual financial statements of the Company and the audit of the annual consolidated financial statements of the Company for the years 2022, 2023 and 2024.For more information: Dominykas MertinasHead of Marketing and Communication DepartmentAKROPOLIS GROUP, UAB+370 64027001dominykas.mertinas@akropolis.lt